Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, KBR, Spirit, and Molina of the Upcoming Deadlines and Urges Investors to Contact the Firm - Spirit Aviation Holdings (OTC:FLYYQ), Jasper Therapeutics (NASDAQ:JSPR)

KBR won a five-year NATO contract with a $60M initial ceiling to support PATRIOT air and missile defense systems and their integration with IBCS. The contract includes command-and-control engineering, technical support, and operational readiness for deployed systems. Work will occur at multiple U.S. locations. KBR has supported the PATRIOT system for about 40 years.

Shares of Centene (CNC), UnitedHealth (UNH), CVS (CVS), and Humana (HUM) fell after-hours Tuesday after a report that the Trump administration plans to end a $3.6B federal subsidy for Medicare Part D plans post-2026. The subsidy helps keep premiums low for 25M enrollees. The loss of support could pressure margins and enrollment for insurers offering stand-alone Part D plans, though some beneficiaries may shift to Medicare Advantage plans.

Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.

KBR said it secured a $208 million U.S. Army cost-plus-fixed-fee task order under OASIS+ for support tied to the TAGM portfolio, including Hellfire, JAGM, Javelin and TOW, plus Hydra rockets and Long-Range Precision Munitions. Work spans engineering, prototyping, modernization, foreign military sales and logistics across the weapons lifecycle.

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030204901ex99-1.htm PRESS RELEASE, DATED AUGUST 14, 2026 Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio

Jasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.